

US008382780B2

(12) United States Patent Birk

54) FATIGUE-RESISTANT GASTRIC BANDING DEVICE

(75) Inventor: Janel Birk, Oxnard (CA)

(73) Assignee: Allergan, Inc., Irvine, CA (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 293 days.

(21) Appl. No.: 12/851,437

(22) Filed: Aug. 5, 2010

(65) **Prior Publication Data**

US 2010/0324359 A1 Dec. 23, 2010

Related U.S. Application Data

- (63) Continuation of application No. 10/492,784, filed on Apr. 18, 2005, now Pat. No. 7,811,298.
- (60) Provisional application No. 60/407,219, filed on Aug. 28, 2002.

(51)	Int. Cl.
	A61B 17/08
	A61F 2/02
	A61F 2/00

(2006.01) (2006.01) (2006.01)

- (52) **U.S. Cl.** **606/157**; 600/31; 600/37

(56) References Cited

U.S. PATENT DOCUMENTS

1 174 914 4	2/1016	Duamman at al
1,174,814 A		Brennan et al.
1,830,947 A	11/1931	Klingel
1,999,683 A	4/1935	Borresen
2,163,048 A	6/1939	McKee
2,339,138 A	1/1944	Black
2,405,667 A	8/1946	Ottesen
2,438,231 A	3/1948	Schultz et al.

(10) Patent No.: US 8,382,780 B2

(45) **Date of Patent:** Feb. 26, 2013

2,635,907 A	4/1953	Heimbuch
2,714,469 A	8/1955	Carlson
2,936,980 A	5/1960	Rapata
3,059,645 A	10/1962	Hasbrouck et al.
3,189,961 A	6/1965	Heller
3,667,081 A	6/1972	Burger
3,840,018 A	10/1974	Heifetz
3,955,834 A	5/1976	Ahlrot
4,053,176 A	10/1977	Hilbush
4,118,805 A	10/1978	Reimels
4,133,315 A	1/1979	Berman et al.
4,157,713 A	6/1979	Clarey
	(Con	tinued)

FOREIGN PATENT DOCUMENTS

CA	949965	6/1974
CN	1250382	4/2000
	(Co	ntinued)

OTHER PUBLICATIONS

Brown et al; "Symmetrical Pouch Dilation After Laparoscopic Adjustable Gastric Banding: Incidence and Management"; Obesity Surgery; V. 18, pp. 1104-1108; 2008.


(Continued)

Primary Examiner — Julian Woo (74) Attorney, Agent, or Firm — Linda Fox; Stephen Donovan; Debra Condino

(57) ABSTRACT

A fatigue-resistant inflatable gastric banding device suitable for laparoscopic placement around the stomach of a patient for the treatment of obesity and a method for such treatment are disclosed. The device includes a gastric band having a chambered inflatable member, substantially coextensive with an inner stomach facing surface of the band, that does not crease, wrinkle or fold when adjusted, so as to present a substantially smooth contour along the inner circumference, and to avoid fatigue or failure of the member itself. A gastric band having multiple inflatable compartments or chambers, which may be inflated together or individually is also disclosed.

12 Claims, 6 Drawing Sheets



II S DATENT	DOCUMENTS	5,704,893 A	1/1998 Timm
		5,713,911 A	2/1998 Racenet et al.
	Peterson Lauterjung	5,733,257 A	3/1998 Sternby
	Angelchik	5,748,200 A	5/1998 Funahashi
4,299,012 A 11/1981	Oetiker	5,766,232 A 5,769,877 A	6/1998 Grevious et al. 6/1998 Barreras, Sr.
	Cummins	5,785,295 A	7/1998 Tsai
4,399,809 A 8/1983 4,408,597 A 10/1983	Baro et al. Tenney, Jr. et al.	5,817,113 A	10/1998 Gifford, III et al.
4,417,567 A 11/1983		5,827,529 A	10/1998 Ono et al.
	Wallace et al.	5,833,698 A 5,861,014 A	11/1998 Hinchliffe et al. 1/1999 Familoni
4,442,153 A 4/1984		RE36,176 E	3/1999 Kuzmak
	Siegal	5,886,042 A	3/1999 Yu et al.
	Foster, Jr. Oetiker	5,904,697 A	5/1999 Gifford, III et al.
4,551,862 A 11/1985		5,910,149 A 5,928,195 A	6/1999 Kuzmak 7/1999 Malamud et al.
, ,	Bashour	5,938,669 A	8/1999 Klaiber et al.
	Owen et al. Smestad et al.	5,944,696 A	8/1999 Bayless et al.
	Balazs et al.	5,944,751 A	8/1999 Laub
	Kuzmak et al.	5,993,473 A 6,013,679 A	11/1999 Chan et al. 1/2000 Kuo et al.
	Antebi	6,024,340 A	2/2000 Lazarus et al.
	Fuqua Romanowski 606/202	6,024,704 A	2/2000 Meador et al.
	Rappe 800/202	6,048,309 A	4/2000 Flom et al.
4,693,695 A 9/1987		6,067,991 A 6,074,341 A	5/2000 Forsell 6/2000 Anderson et al.
	Weiner et al.	6,074,341 A 6,074,378 A	6/2000 Mouri et al.
	Kuzmak et al.	6,083,249 A	7/2000 Familoni
	Malson et al.	6,090,131 A	7/2000 Daley
	Schmidt	6,102,678 A 6,102,922 A	8/2000 Peclat 8/2000 Jakobsson et al.
4,760,837 A 8/1988		6,171,321 B1	1/2001 Gifford, III et al.
	Wallace et al.	6,193,734 B1	2/2001 Bolduc et al.
	Newman Franetzki et al.	6,203,523 B1	3/2001 Haller et al.
	de Belder et al.	6,210,345 B1 6,210,347 B1	4/2001 Van Brunt 4/2001 Forsell
	Delamour et al.	6,221,024 B1	4/2001 Forsell 4/2001 Miesel
	Cone et al.	6,224,857 B1	5/2001 Romeo et al.
	Garay et al. Holtermann	6,306,088 B1	10/2001 Krausman et al.
	Labbe et al.	6,327,503 B1 6,371,965 B2	12/2001 Familoni 4/2002 Gifford, III et al.
· · · · · · · · · · · · · · · · · · ·	Nakamura	6,372,494 B1	4/2002 Official, if et al.
	Cox, Jr. Fernandez et al.	6,383,218 B1	5/2002 Sourdille et al.
	Melsky et al.	6,383,219 B1	5/2002 Telandro et al.
	Kuzmak	6,387,105 B1 6,417,750 B1	5/2002 Gifford, III et al. 7/2002 Sohn
	Gau et al.	6,418,934 B1	7/2002 Solin 7/2002 Chin
	Yu et al. Alzner	6,419,696 B1	7/2002 Ortiz et al.
	Elftman	6,432,040 B1	8/2002 Meah
5,143,724 A 9/1992	Leshchiner et al.	6,439,539 B1 6,443,957 B1	8/2002 Powell 9/2002 Addis
	Bengmark et al.	6,443,965 B1	9/2002 Addis 9/2002 Gifford, III et al.
, ,	Vincent Bayless et al.	6,450,173 B1	9/2002 Forsell
	Enhorning	6,450,946 B1	9/2002 Forsell
5,226,429 A 7/1993	Kuzmak	6,451,034 B1 6,453,907 B1	9/2002 Gifford, III et al. 9/2002 Forsell
	Wilkinson	6,454,699 B1	9/2002 Forsell
5,246,698 A 9/1993 5,259,399 A 11/1993	Leshchiner et al. Brown	6,454,700 B1	9/2002 Forsell
	Baraff	6,454,701 B1 6,454,785 B2	9/2002 Forsell 9/2002 De Hoyos Garza
5,343,894 A 9/1994	Frisch et al.	6,457,801 B1	10/2002 Fish et al.
	Kuo et al.	6,460,543 B1	10/2002 Forsell
5,360,445 A 11/1994 5,391,156 A 2/1995		6,461,293 B1	10/2002 Forsel1
	Leshchiner et al.	6,463,935 B1 6,464,628 B1	10/2002 Forsell 10/2002 Forsell
5,449,363 A 9/1995		6,470,892 B1	10/2002 Forsell
5,449,368 A 9/1995		6,474,584 B2	11/2002 Ekich
5,458,568 A 10/1995 5,509,888 A 4/1996	Racchini et al. Miller	6,475,136 B1	11/2002 Forsell
	Luzio et al.	6,485,496 B1	11/2002 Suyker et al.
5,535,752 A 7/1996	Halperin et al.	6,491,704 B2 6,491,705 B2	12/2002 Gifford, III et al. 12/2002 Gifford, III et al.
	Novak et al.	6,511,490 B2	1/2003 Robert
	Grevious Vincent	6,517,556 B1	2/2003 Monassevitch
5,607,418 A 3/1997		6,527,701 B1	3/2003 Sayet et al.
5,633,001 A 5/1997	Agerup	6,547,801 B1	4/2003 Dargent et al.
5,653,718 A 8/1997		6,565,582 B2 6,579,301 B1	5/2003 Gifford, III et al. 6/2003 Bales et al.
	Vincent et al. Larson, Jr. et al.	6,601,604 B1	8/2003 Cooper
	Gifford, III et al.	6,615,084 B1	9/2003 Cigaina
		•	-

6,627,620 B1	9/2003	Nielsen	7,758,493	B2	7/2010	Gingras
6,630,486 B1	10/2003	Rover	7,763,039	B2	7/2010	Ortiz et al.
6,632,239 B2		Snyder et al.	7,766,815		8/2010	
6,646,628 B2		Shirochi et al.	7,771,439			Griffiths
6,676,674 B1	1/2004		7,775,215			Hassler, Jr. et al.
6,685,668 B1		Cho et al.	7,775,966			Dlugos et al.
6,685,963 B1	2/2004	Taupin et al.	7,775,967	B2	8/2010	Gertner
6,691,047 B1	2/2004	Fredericks	7,794,386	B2	9/2010	Brooks
6,715,731 B1		Post et al.	7,811,298		10/2010	
		Mattes et al.				
6,729,600 B2			7,824,422			Benchetrit
6,754,527 B2		Stroebel et al.	7,828,813		11/2010	Mouton
6,767,924 B2	7/2004	Yu et al.	7,832,407	B2	11/2010	Gertner
6,811,136 B2	11/2004	Eberhardt et al.	7,841,978	B2	11/2010	Gertner
6,820,651 B2	11/2004	Seuret et al.	7,844,342	B2	11/2010	Dlugos, Jr. et al.
6,834,201 B2		Gillies et al.	7,862,502		1/2011	Pool et al.
6,871,090 B1		He et al.	7,879,068		2/2011	Dlugos et al
6,889,086 B2		Mass et al.	7,951,067		5/2011	Byrum et al.
6,916,326 B2	7/2005	Benchetrit	2001/0011543	A1	8/2001	Forsell
6,921,819 B2	7/2005	Piron et al.	2002/0072780	A1	6/2002	Foley
6,924,273 B2	8/2005		2002/0091395		7/2002	Gabbay
						Beyar
6,940,467 B2		Fischer et al.	2002/0095181		7/2002	
6,966,875 B1		Longobardi	2002/0098097		7/2002	Singh
7,017,583 B2	3/2006	Forsell	2002/0139208	A1	10/2002	Yatskov
7,021,147 B1	4/2006	Subramanian et al.	2002/0183765	A1	12/2002	Adams
7,037,344 B2	5/2006	Kagan et al.	2002/0193679	A1	12/2002	Malave et al.
7.040,349 B2		Moler et al.	2002/0198548		12/2002	Robert
, ,	5/2006		2003/0014003			
7,054,690 B2						Gertner
7,058,434 B2		Wang et al.	2003/0019498		1/2003	Forsell
7,060,080 B2	6/2006	Bachmann	2003/0045775	A1	3/2003	Forsel1
7,118,526 B2	10/2006	Egle	2003/0045902	A1	3/2003	Weadock
7,119,062 B1		Alvis et al.	2003/0060873			Gertner et al.
					4/2003	
7,128,750 B1		Stergiopulos	2003/0066536			
7,144,400 B2		Byrum et al.	2003/0073880		4/2003	Polsky et al.
7,172,607 B2	2/2007	Hofle et al.	2003/0093157	A1	5/2003	Casares et al.
7,177,693 B2	2/2007	Starkebsum	2003/0100910	A1	5/2003	Gifford, III et al.
7,191,007 B2		Desai et al.	2003/0120288		6/2003	Benchetrit
7,204,821 B1		Clare et al.	2003/0148995			Piron et al.
7,223,239 B2		Schulze et al.	2003/0158564			Benchetrit
7,238,191 B2	7/2007	Bachmann	2003/0158569	Al	8/2003	Wazne
7,240,607 B2	7/2007	Fish	2003/0181890	A1	9/2003	Schulze et al.
7,255,675 B2	8/2007	Gertner et al.	2003/0181917	A1	9/2003	Gertner
7,263,405 B2		Boveja et al.	2003/0191433		10/2003	Prentiss
7,282,023 B2	10/2007		2003/0208212		11/2003	
						Cigaina
7,288,064 B2		Boustani et al.	2004/0000843		1/2004	East
7,297,103 B2	11/2007	Jarsaillon et al.	2004/0044332	A1	3/2004	Stergiopulos
7,299,082 B2	11/2007	Feldman et al.	2004/0049209	A1	3/2004	Benchetrit
7,310,557 B2	12/2007	Maschino et al.	2004/0059393	A1	3/2004	Policker et al.
7,311,716 B2	12/2007		2004/0068847		4/2004	Belisle et al.
7,311,717 B2	12/2007		2004/0106899		6/2004	McMichael et al.
7,314,443 B2	1/2008		2004/0133219		7/2004	Forsell
7,314,636 B2		Caseres et al.	2004/0147816	Al	7/2004	Policker et al.
7,338,433 B2	3/2008	Coe	2004/0148034	A1	7/2004	Kagan et al.
7,340,306 B2	3/2008	Barrett et al.	2004/0153106	A1	8/2004	Dudai
7,351,198 B2		Byrum et al.	2004/0162595		8/2004	
7,351,240 B2		Hassler, Jr. et al.	2004/0215159		10/2004	,
7,331,240 D2						
7,364,542 B2		Jambor et al.	2004/0230137		11/2004	
7,367,340 B2		Nelson et al.	2004/0254536			Conlon et al.
7,367,937 B2	5/2008	Jambor et al.	2004/0254537	Al	12/2004	Conlon et al.
7,374,565 B2	5/2008	Hassler, Jr. et al.	2004/0260319	A1	12/2004	Egle
7,390,294 B2	6/2008	Hassler, Jr.	2004/0267288	A1	12/2004	Byrum et al.
7,396,353 B2		Lorenzen et al.	2004/0267291		12/2004	Byrum et al.
7,416,528 B2		Crawford et al.	2004/0267292		12/2004	Byrum et al.
7,457,668 B2		Cancel et al.	2004/0267293		12/2004	Byrum et al.
7,481,763 B2		Hassler, Jr. et al.	2004/0267377		12/2004	
7,500,944 B2	3/2009	Byrum et al.	2005/0002984	A1	1/2005	Byrum et al.
7,502,649 B2	3/2009	Ben-Haim et al.	2005/0038484	A1	2/2005	Knudson et al.
7,530,943 B2		Lechner	2005/0038498		2/2005	Dubrow et al.
7,594,885 B2	9/2009		2005/0055039		3/2005	Burnett et al.
7,599,743 B2	10/2009	Hassler, Jr. et al.	2005/0070934		3/2005	Tanaka et al.
7,599,744 B2		Giordano et al.	2005/0070937		3/2005	Jambor et al.
7,601,162 B2	10/2009	Hassler, Jr. et al.	2005/0100779	A1	5/2005	Gertner
7,615,001 B2	11/2009	Jambor et al.	2005/0104457		5/2005	Jordan et al.
7,618,365 B2	11/2009	Jambor et al.	2005/0119672		6/2005	Benchetrit
7,658,196 B2		Ferreri et al.	2005/0119674		6/2005	Gingras
7,670,279 B2	3/2010	Gertner	2005/0131383	A1	6/2005	Chen et al.
7,699,770 B2		Hassler, Jr. et al.	2005/0131485		6/2005	Knudson et al.
7,712,470 B2		Gertner	2005/0136122		6/2005	Sadozai et al.
7,727,141 B2		Hassler, Jr. et al.	2005/0142152		6/2005	Leshchiner et al.
7,741,476 B2	6/2010	Lebreton	2005/0143765	Al	6/2005	Bachmann et al.

2005/0143766 A1	6/2005	Bachmann et al.	2007/0179335 A1		Gertner et al.
2005/0154274 A1	7/2005	Jarsaillon et al.	2007/0185373 A1	8/2007	Tsonton
2005/0171568 A1	8/2005	Duffy	2007/0185462 A1	8/2007	Byrum
2005/0183730 A1	8/2005	Byrum	2007/0213836 A1	9/2007	Paganon
2005/0192531 A1	9/2005	Birk	2007/0218083 A1	9/2007	Brooks
2005/0192601 A1	9/2005	Demarais	2007/0232848 A1	10/2007	Forsell
2005/0192629 A1		Saadat et al.	2007/0232849 A1	10/2007	
2005/0216042 A1		Gertner	2007/0233170 A1	10/2007	Gertner
2005/0226936 A1	10/2005		2007/0235083 A1	10/2007	
2005/0228415 A1	10/2005		2007/0243227 A1	10/2007	
2005/0228504 A1		Demarais	2007/0250085 A1		Bachmann et al.
2005/0220304 A1 2005/0240155 A1	10/2005		2007/0250085 A1 2007/0250086 A1		Wiley et al.
2005/0240156 A1	10/2005		2007/0255335 A1		Herbert et al.
2005/0240130 A1 2005/0240279 A1		Kagan et al.	2007/0255336 A1 2007/0255336 A1		Herbert et al.
2005/0240279 A1 2005/0244288 A1					
	11/2005		2007/0265598 A1	11/2007	
2005/0250979 A1	11/2005		2007/0265645 A1		Birk et al.
2005/0251181 A1		Bachmann	2007/0265646 A1		McCoy et al.
2005/0251182 A1		Bachmann	2007/0293716 A1		Baker et al.
2005/0267406 A1		Hassler, Jr.	2007/0298005 A1		Thibault
2005/0267500 A1		Hassler, Jr.	2008/0009680 A1		Hassler, Jr.
2005/0267533 A1	12/2005		2008/0015406 A1		Dlugos et al.
2005/0271729 A1		Wang	2008/0015501 A1		Gertner
2005/0277899 A1	12/2005		2008/0027269 A1		Gertner
2005/0283041 A1	12/2005		2008/0027469 A1		Bachmann
2005/0288739 A1		Hassler, Jr. et al.	2008/0071306 A1		Gertner
2005/0288740 A1		Hassler, Jr. et al.	2008/0097496 A1		Chang et al.
2006/0015138 A1	1/2006	Gertner	2008/0108862 A1	5/2008	Jordan et al.
2006/0020298 A1	1/2006	Camilleri et al.	2008/0147002 A1	6/2008	Gertner
2006/0041183 A1	2/2006	Massen et al.	2008/0161717 A1	7/2008	Gertner
2006/0074439 A1	4/2006	Garner et al.	2008/0161875 A1	7/2008	Stone
2006/0074473 A1	4/2006	Gertner	2008/0167647 A1	7/2008	Gertner
2006/0089571 A1		Gertner	2008/0167648 A1		Gertner
2006/0122147 A1		Wohlrab	2008/0172072 A1		Pool et al.
2006/0142700 A1	6/2006	Sobelman et al.	2008/0188766 A1		Gertner
2006/0142790 A1		Gertner	2008/0195092 A1		Kim et al.
2006/0161139 A1		Levine et al.	2008/0208240 A1	8/2008	
2006/0161186 A1		Hassler, Jr. et al.	2008/02205246 A1		Dlugos et al.
2006/0167531 A1		Gertner et al.	2008/0243071 A1		Quijano et al.
2006/0107331 A1 2006/0173238 A1		Starkebaum	2008/0249806 A1		Dlugos et al.
2006/01/3238 A1 2006/0173424 A1		Conlon	2008/0249800 A1 2008/0250340 A1		Dlugos et al.
		Lechner			
2006/0183967 A1		Hassler, Jr. et al.	2008/0250341 A1		Dlugos et al.
2006/0189887 A1			2008/0255403 A1		Voegele et al.
2006/0189888 A1		Hassler, Jr. et al.	2008/0255414 A1		Voegele et al.
2006/0189889 A1		Gertner	2008/0255425 A1		Voegele et al.
2006/0194758 A1		Lebreton	2008/0255459 A1		Voegele et al.
2006/0195139 A1		Gertner	2008/0255537 A1		Voegele et al.
2006/0197412 A1		Rasmussen	2008/0275294 A1	11/2008	
2006/0199997 A1	9/2006	Hassler, Jr. et al.	2008/0275295 A1	11/2008	
2006/0211912 A1		Dlugos et al.	2008/0275484 A1	11/2008	
2006/0211913 A1		Dlugos et al.	2008/0281347 A1	11/2008	Gertner
2006/0211914 A1	9/2006	Hassler, Jr. et al.	2008/0287969 A1	11/2008	Tsonton et al.
2006/0212051 A1	9/2006	Snyder et al.	2008/0287974 A1		Widenhouse et al.
2006/0212053 A1	9/2006	Gertner	2008/0287976 A1		Weaner et al.
2006/0235448 A1	10/2006	Roslin et al.	2008/0300618 A1	12/2008	Gertner
2006/0246137 A1	11/2006	Hermitte et al.	2008/0319435 A1	12/2008	Rioux et al.
2006/0247721 A1		Maschino et al.	2009/0054914 A1		Lechner
2006/0247722 A1		Maschino et al.	2009/0062825 A1	3/2009	Pool et al.
2006/0252982 A1		Hassler, Jr.	2009/0062826 A1		Steffen
2006/0252983 A1	11/2006	Lembo et al.	2009/0082793 A1	3/2009	
2006/0257488 A1	11/2006	Hubbard	2009/0118572 A1	5/2009	Lechner
2006/0264699 A1	11/2006	Gertner	2009/0149874 A1	6/2009	Ortiz et al.
2006/0276812 A1	12/2006	Hill et al.	2009/0157106 A1	6/2009	Marcotte et al.
2006/0293627 A1	12/2006	Byrum et al.	2009/0157107 A1	6/2009	Kierath et al.
2007/0015954 A1	1/2007	Dlugos	2009/0157113 A1	6/2009	Marcotte et al.
2007/0015955 A1	1/2007	Tsonton	2009/0171375 A1		Coe et al.
2007/0015956 A1		Crawford et al.	2009/0171378 A1		Coe et al.
2007/0016231 A1		Jambor et al.	2009/0171379 A1		Coe et al.
2007/0016262 A1		Gross et al.	2009/0187202 A1		Ortiz et al.
2007/0027356 A1	2/2007		2009/0192404 A1		Ortiz et al.
2007/0027358 A1		Gertner et al.	2009/0192415 A1		Ortiz et al.
2007/0044655 A1	3/2007		2009/0192533 A1		Dlugos, Jr. et al.
2007/0077292 A1		Pinsky	2009/0192534 A1 2009/0192534 A1		Ortiz et al.
		,			
2007/0078476 A1		Hull, Sr. et al.	2009/0192541 A1		Ortiz et al.
2007/0125826 A1		Shelton	2009/0198261 A1	8/2009	
2007/0156013 A1	7/2007		2009/0202387 A1		Dlugos, Jr. et al.
2007/0167672 A1		Dlugos et al.	2009/0204131 A1		Ortiz et al.
2007/0167982 A1		Gertner et al.	2009/0204132 A1		Ortiz et al.
2007/0173685 A1	7/2007	Jambor et al.	2009/0209995 A1	8/2009	
2007/0173888 A1	7/2007	Gertner et al.	2009/0216255 A1	8/2009	Coe et al.

2009/0220176	A1 9/2	2009 Fusco	FR	2921822	4/2009
2009/0222031		2009 Axelsson	GB	1174814	12/1969
2009/0222065		2009 Dlugos, Jr. et al.	GB	2090747	7/1982
2009/0228063		2009 Dlugos, Jr. et al.	JP	57-171676	10/1982
2009/0228072		2009 Coe et al.	JP	1-67309	4/1989
2009/0270904		2009 Birk et al.	JP	2-019147	1/1990
2009/0306462		2009 Lechner	JP	2-132104	11/1990
2010/0010291		2010 Birk et al.	JР	3-105702	11/1991
2010/0049224		2010 Vargas	JP	11-244395	9/1999
2010/0087843		2010 Bertolote et al.	JP	2003-526410	9/2003
2010/00097045		2010 Birk et al.	JP	2005-131380	5/2005
2010/0100079		2010 Birk et al.	JP	2005-334658	12/2005
2010/0145378		2010 Gertner	SE	8503144	12/1986
2010/0152532		2010 Marcotte	WO	WO 86/00079	1/1986
2010/0152532		2010 Gertner	wo	WO 86/00073	2/1986
2010/0108308		2010 Germer 2010 Birk et al.	WO	WO 89/11701	11/1989
2010/0193049		2010 Blik et al.	WO	WO 90/00369	1/1990
2010/0191203		2010 Lau et al.	wo	WO 92/20349	11/1992
2010/01912/1		2010 Gertner	WO	WO 94/02517	2/1994
2010/0204047		2010 Gertner	WO	WO 96/33751	1/1996
2010/0204723		2010 Germer 2010 Ricol	WO	WO 98/35639	8/1998
2010/021/071		2010 Rebreton	WO	WO 98/35640	8/1998
		2010 Tavori et al.	WO		
2010/0228080 2010/0234682		2010 Tavorret at. 2010 Gertner	WO	WO 00/00108	1/2000
		2010 Geither 2010 Griffiths	WO	WO 00/01428	1/2000
2010/0249803				WO 00/09047	2/2000
2010/0280310		2010 Raven	WO	WO 00/09049	2/2000
2010/0305397		2010 Birk et al.	WO	WO 00/15158	3/2000
2010/0312046		2010 Lau et al.	WO	WO 00/66196	11/2000
2010/0312147		2010 Gertner	WO	WO 01/10359	2/2001
2010/0324358	A1 12/2	2010 Birk et al.	WO	WO 01/12078	2/2001
2011/0201874	A1 8/2	2011 Birk et al.	WO	WO 01/41671	6/2001
			WO	WO 01/47435	7/2001
FO	REIGN P	ATENT DOCUMEN		WO 01/47575	7/2001
CN	1367670	9/2002	WO	WO 01/49245	7/2001
DE	4225524	2/1994	WO	WO 01/52777	7/2001
DE	10020688	12/2000	WO	WO 01/68007	9/2001
EP	0119596	9/1984	WO	WO 01/85071	11/2001
EP	0230747	8/1987	WO	WO 02/05753	1/2002
EP	0416250	3/1991	WO	WO 02/09792	2/2002
EP	0611561	8/1994	WO	WO 02/019953	3/2002
EP	0695558	2/1996	WO	WO 02/26317	4/2002
EP	0876808	11/1998	WO	WO 02/053093	7/2002
EP	1036545	9/2000	WO	WO 02/065948	8/2002
EP	1072282	1/2001	WO	WO 02/096326	12/2002
EP	1105073	6/2001	WO	WO 02/090320 WO 03/007782	1/2002
EP	1396242	3/2004	WO	WO 03/007/82 WO 03/055420	7/2003
EP	1396243	3/2004			
EP	1491167	12/2004	WO	WO 03/057092	7/2003
EP	1491168	12/2004	WO	WO 03/059215	7/2003
EP	1529502	5/2005	WO	WO 03/077191	9/2003
EP	1547549	6/2005	WO	WO 03/101352	12/2003
EP	1574189	9/2005	WO	WO 03/105732	12/2003
EP	1600183	11/2005	WO	WO 2004/014245	2/2004
EP	1602346	12/2005	WO	WO 2004/019671	3/2004
EP	150 1000	0/2006	WO	WO 2004/108025	12/2004
EP	1704833	9/2006 11/2006	WO	WO 2004/112563	12/2004
EP	1736123	12/2006	WO	WO 2005/007232	1/2005
EP	1736125	12/2006	WO	WO 2005/009305	2/2005
EP	1736202	12/2006	WO	WO 2005/067994	7/2005
EP	1730202	1/2007	wo	WO 2005/072195	8/2005
EP		9/2007	WO	WO 2005/072193 WO 2005/087147	9/2005
EP	1829504 1829505	9/2007		WO 2005/08/14/ WO 2005/094447	
			WO		10/2005
EP	1829506	9/2007	WO	WO 2005/112888	12/2005
EP	1967168	9/2008 11/2008	WO	WO 2006/040647	4/2006
EP	1992315		WO	WO 2006/049725	5/2006
EP	2074970	7/2009	WO	WO 2006/083885	8/2006
EP	2074971	7/2009	WO	WO 2006/108203	10/2006
EP	2074972	7/2009	WO	WO 2007/067206	6/2007
EP	2095796	9/2009	WO	WO 2007/081304	7/2007
EP	2095798	9/2009	WO	WO 2007/106727	9/2007
EP	2191796	6/2010	wo	WO 2007/114905	10/2007
FR	1566202	5/1969	WO	WO 2007/145638	12/2007
FR	2688693	9/1993	wo	WO 2008/063673	5/2008
FR	2769491	4/1999	WO	WO 2008/003073 WO 2008/134755	11/2008
FR	2783153	3/2000	WO		
FR	2797181	2/2001	WO	WO 2009/050709	4/2009
FR	2799118	4/2001		WO 2009/132127	10/2009
FR	2823663	10/2002	WO	WO 2009/136126	11/2009
FR	2855744	12/2004	WO	WO 2010/042493	4/2010

OTHER PUBLICATIONS

Ceelen et al.; "Surgical Treatment of Severe Obesity With a Low-Pressure Adjustable Gastric Band: Experimental Data and Clinical Results in 625 Patients"; Annals of Surgery; V. 237, No. 1; pp. 10-16; 2003.

Dixon et al.; "Pregnancy After Lap-Band Surgery: Management of the Band to Achieve Healthy Weight Outcomes"; Obesity Surgery; V. 11, pp. 59-65; 2001.

Neary et al.; "Peptide YY(3-36) and Glucagon-Like Peptide-1₍₇₋₃₆₎ Inhibit Food Intake Additively"; Endocrinology; V.146; pp. 5120-5127; 2005.

Padidela et al.; "Elevated basal and post-feed glucagon-like petide 1 (GLP-1) concentrations in the neonatel period"; European Journal of Endocrinology; v. 160; pp. 53-58; 2009.

Shi et al., "Sexually Dimorphic Responses to Fat Loss After Caloric Restriction or Surgical Lipectomy"; Am. J. Physiol. Endocrinol. Metab., V. 293; E316-E326; 2007.

Xanthakos et al.; "Bariatric Surgery for Extreme Adolescent Obesity: Indications, Outcomes, and Physiologic Effects on the Gut-Brain Axis"; Pathophysiology; V. 15; pp. 135-146; 2008.

"Innovative medical devices and implants"; LGSP medical futures, p. 5

Acuna-Goycolea et al.; "Mechanism of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Inhibition of Identified Green Fluorescent Protein-Expressing GABA Neurons in the Hypothalamic Neuroendocrine Acruate Nucleus"; The Journal of Neuroscience; V. 25(32); pp. 7406-7419; Aug. 10, 2005.

Adrian et al.; "Mechanism of Pancreatic Polypeptide Release in Man." The Lancet; pp. 161-163; Jan. 22, 1977.

Anson; "Shape Memory Alloys—Medical Applications," Source: Materials World, vol. 7, No. 12, pp. 745-747, Dec. 1999.

Asakawa et al; "Antagonism of Ghrelin Receptor Reduces Food Intake and Body Weight Gain in Mice"; Gut.; V.52; pp. 947-952; 2003.

Baggio et al. "Biology of Incretins: GLP-1 and GIP"; Gastroenrology; V. 132; pp. 2131-2157; 2007.

Ballantyne; "Peptide YY(1-36) and Peptide YY(3-36): Part I. Distribution, Release, and Actions"; Obesity Surgery; V.16; pp. 651-658; 2006

Ballantyne; "Peptide YY(1-36) and Peptide YY(3-36): Part II. Changes after Gastrointestinal Surgery and Bariatric Surgery"; Obesity Surgery; V.16; pp. 795-803; 2006.

Berne et al; "Physiology"; V. 5; pp. 55-57, 210, 428, 540, 554, 579, 584, 591; 2004.

BioEnterics Lap-Band Adjustable Gastric Banding System, Inamed Health, pub., pp. 1-115; Aug. 28, 2003.

Boulant et al.; "Cholecystokinin in Transient Lower Oesophageal Sphincter Relaxation Due to Gastric Distension in Humans"; Gut.; V. 40; pp. 575-581; 1997.

Bradjewin et al.; "Dose Ranging Study of the Effects of Cholecystokinin in Healthy Volunteers"; J. Psychiatr. Neurosci.; V. 16 (2); pp. 91-95; 1991.

Burdyga et al.; "Cholecystokinin Regulates Expression of Y2 Receptors in Vagal Afferent Neurons Serving the Stomach"; The Journal of Neuroscience; V. 28; No. 45; pp. 11583-11592; Nov. 5, 2008.

Chaptini et al.; "Neuroendocrine Regulation of Food Intake"; Current Opinion in Gastroenterology; V. 24; pp. 223-229; 2008.

Chaudhri; "Can Gut Hormones Control Appetite and Prevent Obesity?" Diabetes Care; V. 31; Supp 2; pp. S284-S289; Feb. 2008.

Cohen et al.; "Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans"; J. Clin. Endocrinol. Metab.; V. 88; No. 10; pp. 4696-4701; 2003.

Corno et al.; "A new implantable device for telemetric control of pulmonary blood flow"; New ideas; received Apr. 24, 2004; received in revised form Jul. 12, 2002; 10 pages.

Corno et al.; "FlowWatchTM in clipped and inclipped position"; Interact Cardio Vase Thorac Surg 2002; 1:46-49; Copyright @ 2002 The European Association for Cardio-thoracic Surgery; 1 page.

Cummings et al.; "Plasma Ghrelin Levels After Diet-Induced Weight Loss or Gastric Bypass Sugery"; N. Engl J. Med; V. 346, No. 21; pp. 1623-1630; May 23, 2002.

Cummings; "Gastrointestinal Regulation of Foot Intake"; The Food Journal of Clinical Investigation; V. 117, N. 1; pp. 13-23; Jan. 2007. Dakin et al.; "Oxyntomodulin Inhibits Food Intake in the Rat"; Endocrinology; V. 142; No. 10; pp. 4244-4250; 2001.

Dakin et al.; "Peripheral Oxyntomodulin Reduces Food Intake and Body Weight gain in Rats"; Endocrinology; V. 145; No. 6; pp. 2687-2695; Jun. 2004.

Davison; "Activation of Vagal-Gastric Mechanoreceptors by Cholecystokinin"; Proc. West. Pharmocol. Soc.; V. 29; pp. 363-366; 1986.

De Waele et al.; "Endoscopic Volume Adjustment of Intragastric Balloons for Intolerance"; Obesity Surgery; V. 11; pp. 223-224; 2001.

De Waele et al.; "Intragastric Balloons for Preoperative Weight Reduction"; Obesity Surgery; V. 58; pp. 58-60; 2001.

Desai et al.; "Molecular Weight of Heparin Using 13C Nuclear Magnetic Resonance Spectroscopy" Journal of Pharmaceutical Science, V. 84, I 2; 1995, Abstract only.

Doldi et al.; "Intragastric Balloon: Another Option for Treatment of Obesity and Morbid Obesity"; Hepato-Gastroenterology; V. 51, N. 55; pp. 294-307; Jan.-Feb. 2004.

Doldi et al.; "Treatment of Morbid Obesity with Intragastric Balloon in Association with Diet"; Obesity Surgery; V. 10, pp. 583-587; 2000. Doldi et al; "Intragastric Balloon in Obese Patients"; Obesity Surgery; V. 10, 578-581; 2000.

Ekblad et al.; "Distribution of Pancreatic Peptide and Peptide-YY"; Peptides; V. 23; pp. 251-261; 2002. El Khoury et al.; "Variation in Postprandial Ghrelin Status Following

El Khoury et al.; "Variation in Postprandial Ghrelin Status Following Ingestion of High-Carbohydrate, High Fat, and High Protein Meals in Males"; Ann Nutr Metab; V. 50; pp. 260-269; 2006.

Galloro et al; "Preliminary Endoscopic Technical Report of an New Silicone Intragastric Balloon in the Treatment of Morbid Obesity"; Obesity Surgery; V. 9, pp. 68-71; 1999.

GinShiCel MH Hydroxy Propyl Methyl Cellulose, Web Page http://www.ginshicel.cn/MHPC.html, Nov. 12, 2008.

Girard; "The incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: Incretins: Concept and physiological functions"; Diabetes and Metabolism; V. 34; pp. 550-559; 2008.

Greenough et al.; "Untangling the Effects of Hunger, Anxiety, and Nausea on Energy Intake During Intravenous Cholecystokinin Octapeptide (CCK-8) Infusion"; Physiology & Behavior; V. 65, No. 2; pp. 303-310; 1998.

Grise et al.; "Peptide YY Inhibits Growth of Human Breast Cancer in Vitro and in Vivo"; Journal of Surgical Research; V. 82; pp. 151-155; 1000

Grundy; "Signaling the State of the Digestive Tract"; Autonomic Neuroscience: Basic and Clinical; V. 125; pp. 76-80; 2006.

Grundy; "Vagal Control of Gastrointestinal Function"; Bailliere's Clinical Gastroenterology; V. 2; No. 1; pp. 23-43; 1988.

Hallden et al. "Evidence for a Role of the Gut Hormone PYY in the Regulation of Intestinal Fatty Acid Binding Protein Transcripts in Differentiated Subpopulations of Intestinal Epithelial Cell Hybrids"; Journal of Biological Chemistry; V. 272 (19); pp. 125916-126000; 1997.

Hameed et al.; "Gut hormones and appetite control." Oral Diseases; V. 15; pp. 18-26; 2009.

Hassan et al.; "Effects of Adjuvants to Local Anesthetics on Their Duration III Experimental Studies of Hyaluronic Acid" Abstract Pub Med [Acta Anesthesiol Scand.; 29 (4): 384-8], 1 page; May 1985.

Hodson et al.; "Management of Obesity with the New Intragastric Balloon"; Obesity Surgery; V. 11, pp. 327-329, 2001.

Holzer; "Gastrointestinal Afferents as Targets of Novel Drugs for the Treatment of Functional Bowel Disorders and Visceral Pain"; European Journal of Pharmacology; V. 429; pp. 177-193; 2001.

Houpt; "Gastrointestinal Factors in Hunger and Satiety." Neuroscience and Behavioral Reviews; V. 6; pp. 145-164; 1982.

Jones; "Molecular, pharmacological, and clinical aspects of liraglutide, a oncedaily human GLP-1 analogue"; Molecular and Cellular Endocrinology; V. 297; pp. 137-140; 2009.

Kerem et al.; "Exogenous Ghrelin Enhances Endocrine and Exocrine Regeneration in Pancreatectomized Rats"; J Gastrointest Surg.; V.13; pp. 775-783, 2009.

Kesty et al.; "Hormone-based therapies in the regulation of fuel metabolism and body weight"; Expert Opin. Biol. Ther.; V. 8; No. 11; pp. 1733-1747; 2008.

Kissileff et al.; "Peptides that Regulate Food Intake: Cholecystokinin and Stomach Distension Combine to Reduce Food Intake in Humans"; Am. J. Physiol. Regul. Integr. Comp. Physiol; V. 285; pp. 992-998; 2003.

Kojima et al.; "A role for pancreatic polypeptide in feeding and body weight regulation." Peptides; V. 28; pp. 459-463; 2007.

Kulicke et al. "Visco-Elastic Properties of Sodium Hyaluronate Solutions," American Institute of Physics; pp. 585-587; 2008.

Lap-Band AP System Adjustable Gastric Banding System With OmniformTM Design: Directions for Use (DFU); Allergan, 16 pages; 2009.

Le Roux et al.; "Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters"; Ann. Surg; V. 243; No. 1; pp. 108-114; Jan. 2006. Liu et al.; "Adjuvant Hormonal Treatment With Peptide YY or Its Analog Decreases Human Pancreatic Carcinoma Growth"; The American Journal of Surgery; V. 171; pp. 192-196; Jan. 1996.

Mathus-Vliegen et al. "Intragastric Balloons for Morbid Obesity: Results, Patient Tolerance and Balloon Life Span"; Br. J. Surg.; V. 77, No. 7, pp. 76-79; Jan. 1990.

Mathus-Vliegen et al. "Treating Morbid and Supermorbid Obesity" International Journal of Gastroenterology; V. 5, No. 1, pp. 9-12; 2000. Medeiros et al.; "Processing and metabolism of Peptide-YY: Pivotal roles of Dipeptidase-IV, Aminopeptidase-P, and Endopeptidase-24. 11"; Endocrinology; V. 134, No. 5; pp. 2088-2094; 1994.

Naslund et al. "Pranidal subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects"; British Journal of Nutrition; V. 91; pp. 439-446; 2004.

Potier et al.; "Protein, amino acids, and the control of food intake"; Current Opinion in Clinical Nutrition and Metabolic Care; V. 12; pp. 54-58: 2009.

Qjan et al.; "Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117"; International Journal of Pharmaceutics; V. 366; pp. 218-220: 2008

Rang et al.; "Pharmacology"; V. 5; pp. 203, 397, 402, 524; 2004. Raybould et al.; "Integration of Postprandial Gastrointestinal Tract: Role of CCK and Sensory Pathways"; Annals of New York Academy of Science; pp. 143-156; 1994.

Renshaw et al. "Peptide YY: A Potential Therapy for Obesity"; Current Drug Targets; V. 6; pp. 171-179; 2005.

Sannino et al.; "Crosslinking of Cellulose Derivatives and Hyaluronic Acid with Water-Soluble Carbodiimide" Polymer 46; pp. 11206-11212; 2005.

Shechter et al.; "Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice"; FEBS Letters; V. 579; pp. 2439-2444; 2005.

Silver et al.; "Physical Properties of Hyaluronic Acid and Hydroxypropylmethylcellulose in Solution: Evaluation of Coating Abillity" Journal of Applied Biomaterials, V. 5; pp. 89-98, 1994. Small et al.; "Gut hormones and the control of appetite"; TRENDS in Endocrinology and Metabolism; V. 15. No. 6; pp. 259-263; Aug. 2004.

Stanley et al.; "Gastrointestinal Satiety Signals III. Glucagon-like Peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide"; Am. J. Physiol Gastrointest Liver Physiol; V. 286; pp. 693-697; 2004. Tezel; "The Science of Hyaluronic Acid Dermal Fillers," Journal of Cosmetic and Laser Therapy (2008) 10: pp. 35-42.

Tolhurst et al.; "Nutritional regulation of glucagon-like peptidel secretion"; J. Physiol.; V. 587, No. 1; pp. 27-32; 2009. Totte et al.; "Weight Reduction by Means of Intragastric Device:

Totte et al.; "Weight Reduction by Means of Intragastric Device: Experience with the Bioenterics Intragastric Balloon"; Obesity Surgery; V. 11, pp. 519-523; 2001.

Tough et al.; "Y₄ Receptors Mediate the Inhibitory Responses of

Tough et al.; "Y₄ Receptors Mediate the Inhibitory Responses of Pancreatic Polypeptide in Human and Mouse Colon Mucosa"; The Journal of Pharmacology and Experimental Therapeutics; V. 319, No. 1; pp. 20-30; 2006.

Tseng et al; "Peptide YY and cancer: Current findings and potential clinical applications"; Peptides; V. 23; pp. 389-395; 2002.

Valassi et al.; "Neuroendocrine control of food intake"; Nut. Metab. & Cariovasc. Disease; V. 18; pp. 158-168; 2008.

Van Der Lely et al.; "Biological, Physiological, Pathophysiological Aspects of Ghrelin"; Endocrine Reviews; V. 25, No. 3; pp. 426-457; 2004

Verdich et al. "A Meta-Analysis of the Effect of Glucagon-Like-Peptide-1 (7-36) Amide on ad Libitum Energy Intake in Humans"; J. Clin. Endocrinal. Metab. V. 86; pp. 4382-4389; Sep. 2001.

Wahlen et al.; "The BioEnterics Intragastric Balloon (BIB): How to Use It"; Obesity Surgery; V. 11; pp. 524-527; 2001.


Wang et al.; "Plasma Ghrelin Modulation in Gastric Band Operation and Sleeve Gastrectomy"; Obes. Surg.; pp. 357-362; 2008.

Weiner et al.; "Preparation of Extremely Obese Patients for Laparoscopic Gastric Banding by Gastric Balloon Therapy"; Obesity Surgery; V. 9, pp. 261-264, 1999.

Wynne et al.; "Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects: A Double-Blind Randomized, Controlled Trial"; Diabetes; V. 54; pp. 2390-2395; 2005.

Yuzuriha et al.; "Gastrointestinal Hormones (anorexigenic peptide YY and orexigenic ghrelin) influence neural tube development"; FASEB J.; V. 21; pp. 2108-2112; 2007.

^{*} cited by examiner






FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8

FATIGUE-RESISTANT GASTRIC BANDING DEVICE

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of and claims the benefit and priority of U.S. application Ser. No. 10/492,784, filed Apr. 18, 2005, now U.S. Pat. No. 7,811,298, which claims the benefit and priority of PCT Application No. PCT/US2003/026678, filed Aug. 26, 2003, which claims the benefit and priority of U.S. Provisional Patent Application No. 60/407, 219, filed Aug. 28, 2002, the entire disclosure of each of these applications is incorporated herein by reference.

BACKGROUND

1. Field of the Invention

The present invention relates generally to surgically 20 implanted gastric bands for encircling the stomach having notches, ribs and/or chambers in the inflatable portion to reduce fatigue or crease fold failure in the device, while increasing the range of adjustment. A method for treating morbid obesity utilizing a fatigue-resistant gastric banding 25 device is also disclosed.

2. Description of the Related Art

A belt-like gastric band for encircling the stomach to control morbid obesity is disclosed by Vincent in U.S. Pat. No. 5,601,604, incorporated herein by reference. The band comprises a belt that can be passed around the stomach and locked into an encircling position in order to create a stoma opening within the stomach. An adjustable portion of the band comprises an inflatable member, which permits fine adjustment of the stoma opening after the stoma is created by locking the band in place. The stoma opening may be adjusted by injecting or withdrawing a fluid into or from an inflatable member. The means for injecting the fluid into the inflatable member usually comprises a fill port located beneath the skin that can be accessed extracorporeally by transdermal injection. Thus, 40 following implantation, the gastric band can be adjusted to enlarge or reduce the stoma as required.

The gastric band is implanted surgically, via open or laparoscopic surgery, which may involve placement of a calibrating apparatus in the stomach to position the stoma and 45 size the pouch created above the stoma. The gastric band is imbricated in position about the stomach to prevent slippage, usually by gastro-gastric sutures (i.e. tissue is wrapped over the band and sutured to itself).

As disclosed by Vincent, the inflatable member or shell is 50 preferably substantially coextensive with an inner stomachfacing surface of the gastric band. Furthermore, it has been observed that the inflatable member should not wrinkle or fold when adjusted, so as to present a substantially smooth contour along the inner circumference. This ensures not only 55 that stomach tissue will not be pinched by the inflatable member, which could lead to discomfort or necrosis, but also protects the shell from a phenomenon known as crease fold failure, which may occur if it is inflated beyond its intended range of adjustment. In the field, it has been observed that 60 silicone or other elastomeric materials commonly used in the manufacture of gastric bands can fatigue or fail if repeatedly compressed, folded, wrinkled, buckled under stress or creased by, for example, over-inflation. This failure mode, which may include abrasion of the opposing surfaces against 65 one another, abrasion of the inner surface of the fold "peak" against the opposing chamber wall, or fatigue of the material

2

at folder intersections (the most highly-stressed areas), is sometimes referred to as crease fold failure.

In some cases, it has also been noted that existing adjustable gastric bands do not provide the overall size or range of adjustment desirable for use in particular patients. For instance, existing gastric bands may be either too large or too small to encircle a patient's stomach, while still allowing for a properly sized stoma. This may be due, for instance, to variations from patient to patient and their individual internal physiologies. Thus, gastric bands are now available in several different sizes, measured according to the circumference of the band (e.g. 9.75 cm, 11 cm, etc.). But due to variations in not only patient physiology, but also in the location and encircling position of the band, the surgical technique used, etc., it may not be evident what size band is necessary until a patient is undergoing surgery. Rather than have a variety of different sizes of gastric bands on hand during the surgical procedure, it would be desirable to have one universal size gastric band available that is adjustable over a wider range than those bands known in the prior art.

If the overall size of the gastric band is increased, the inflatable shell portion may not be capable of being adjusted to form a relatively small stoma without creases, wrinkles or folds forming on the inner stomach-facing surface, which may lead to fatigue or failure of the inflatable member, necessitating additional surgery. It would therefore be desirable to provide a universal size of a fatigue-resistant gastric band having an inflatable member that can be adjusted over a wide range of stoma openings.

OBJECTS OF THE INVENTION

The foregoing demonstrates a need for a surgically implantable gastric band having a universal size and offering a range of adjustability suitable for use in a variety of patients.

It is therefore an object of the present invention to provide a gastric band universally sized for use in patients with varying internal physiologies.

It is another object of the present invention to provide a gastric band having an inflatable member adjustable over a wider range of stoma openings than currently available devices.

It is yet another object of the present invention to provide a gastric band having an inflatable member that is substantially coextensive with an inner stomach-facing surface of the gastric band.

Still another object of the present invention is to provide a gastric band having an inflatable member that does not wrinkle or fold when adjusted over a wide range, so as to present a substantially smooth contour along the inner circumference, and to avoid fatigue or failure of the member itself.

Various other objects, advantages and features of the present invention will become readily apparent from the ensuing detailed description and the novel features will be particularly pointed out in the appended claims.

SUMMARY OF THE INVENTION

A preferred embodiment of the invention provides a fatigue-resistant gastric banding device for the treatment of morbid obesity. The device has a gastric band suited for laparoscopic placement around the stomach of a patient to form an adjustable stoma opening. The gastric band has a multi-chambered inflatable member for adjusting the inner circumference of the band. The inflatable member is preferably substantially coextensive with an inner stomach-facing

surface of the gastric band. The inflatable member is chambered so as to not wrinkle or fold when adjusted over its range of adjustment, thereby presenting a substantially smooth contour along the inner circumference and reducing fatigue or failure of the device.

Another embodiment of the present invention is a gastric band having an inflatable shell including a plurality of chambers. Separating the chambers is at least one notch and/or reinforcing rib. Upon inflation of the gastric band, the chambers, ribs and/or notches eliminate creasing, folding or wrinkling of said inflatable shell, thereby reducing fatigue on the device.

Yet another embodiment of the present invention is a method of treating morbid obesity. The method of treatment includes the steps of providing a gastric band having an inflatable shell with a plurality of chambers, ribs and/or notches. A further step requires placing the gastric band around the stomach of a patient to be treated for morbid obesity, and inflating the gastric band to form a stoma.

The fatigue-resistant gastric band of the present invention may be adjusted by adding fluid to or removing fluid from the chambered inflatable member or shell by means of a subcutaneous access port, via a remotely controllable pump, using pressurized fluid or through other means well known to one 25 skilled in the art.

BRIEF DESCRIPTION OF THE DRAWINGS

The following detailed description given by way of ³⁰ example, but not intended to limit the invention solely to the specific embodiments described, may best be understood in conjunction with the accompanying drawings in which:

FIG. 1 is a top view of a gastric band according to one embodiment of the present invention;

FIG. 2 is a cross-sectional view of the gastric band shown in FIG. 1 taken along line 2-2;

FIG. 3 is a top and side view of the encircling portion of a fatigue-resistant inflatable shell of the gastric band of FIG. 1;

FIG. **4** is a cross-sectional top view of the fatigue-resistant 40 inflatable shell of FIG. **3** taken along line **4-4**;

FIG. 5 is a close up cross-sectional view of a convolution point of the fatigue-resistant inflatable shell of FIG. 4 taken in area 5;

FIG. **6** is a cross-sectional view of the fatigue-resistant 45 inflatable shell of FIG. **3** taken along line **6-6** showing the relative thickness of a reinforcing rib;

FIG. 7 is a perspective view of the encircling portion of a fatigue-resistant inflatable shell of a gastric band according to the present invention; and

FIG. 8 is a top and side view of a portion of the gastric band of FIG. 1 straightened to show the width and projection of the chambers in relation to the inner band portion.

DETAILED DESCRIPTION

An inflatable gastric band 10 according to the present invention is shown in FIG. 1. The gastric band 10 has a body portion 11 and an inflatable portion or shell 16. The body portion 11 has a head end 12 and a tail end 13. The head end 60 12 of the body portion 11 has a buckle 19 with a pull-tab 18. The tail end 13 includes a belt tab 17. Upon insertion of the tail end 13 including a fill tube 14 through the buckle 19, the tail end 13 is drawn through the buckle 19 until the belt tab 17 catches on the exit side 20. In this position the gastric band 10 65 is releasably locked in a closed loop position and secured by the buckle 19 and the belt tab 17.

4

The fill tube 14, which is generally a tube having a single lumen (not shown) coextensive therewith, is connected to an end of the gastric band 10. In FIG. 1 it is shown attached to the tail end 13 and in fluid communication with an inflatable shell 16. It will be apparent to one of skill in the art that other arrangements of the fill tube 14 could be made including attachment to the head end 12 without departing from the scope of the present invention.

The inflatable shell 16 is formed to receive the body portion 11 as shown in FIG. 2, which is a cross sectional view of FIG. 1 taken along line 2-2. The inflatable shell 16 is preferably substantially coextensive with the body portion 11, as shown in FIG. 1. The body portion 11 may be attached to the interior of the inflatable shell 16 through the use of adhesives compatible for use within the body or other methods known to those skilled in the art of implantable medical device manufacture. The inflatable shell 16 includes an inner stomachfacing surface 15 that forms a stoma when placed around the stomach. It is this surface that has traditionally been the location of failure due to crease fold fatigue.

To reduce the potential for crease fold failure or high stresses in the inner surface 15, the inflatable shell 16 has pre-formed stress-reducing notches 8 separating chambers 6. FIG. 3 shows a top view of the inflatable shell 16 of gastric band 10 with plurality of chambers 6 each separated by a respective notch 8. FIG. 3 differs from FIG. 1 in that it shows just the inflatable shell 16 without the inner portion 11 of the gastric band 10.

Similarly, FIG. 4 shows a cross-sectional top view of the inflatable shell 16 shown in FIG. 3. In FIG. 4, the inside of the inflatable shell 16 is depicted with reinforcing ribs 7 at each of the notches 8 separating each of the chambers 6. However, as shown in FIG. 3, the first chamber 24 and the last chamber 26 of the inflatable shell 16 may be formed with only one rib 7.

The band may be formed with a single notch 8 along the inner stomach-facing surface 15 of the inflatable shell 16, or more preferably, with multiple notches 8. Similarly, the band may be formed with a single reinforcing rib 7 inside the inflatable shell 16, or more preferably, with multiple ribs 7. Most preferably, the inflatable shell 16 is formed with corresponding ribs 7 and notches 8. The notches 8, chambers 6, and ribs 7 are formed in the inflatable shell 16 during the manufacturing process and are a feature of the inflatable shell 16 of the gastric band 10 whether filled or unfilled (i.e. whether the band is inflated or un-inflated). This helps to ensure that upon initial positioning of the gastric band 10 there is no pinching of the stomach.

FIG. 6 shows a cross sectional view of the inflatable shell 16 of FIG. 3 taken along line 6-6. In FIG. 6, the thickness of the rib 7 can be seen relative to the thickness of the inflatable shell 16. FIG. 6 also shows that the width of the chambers 6 may extend beyond the width of an outer surface 22 of the inflatable shell 16. Similarly, FIG. 8 shows the chambers 6 extending beyond the width of the body portion 11 (designated by the dotted line). The greater size of the chambers 6 relative to the body portion 11 helps to evenly distribute the forces applied to the stomach through the inflation of the gastric band 10.

FIG. 5 shows a close-up view of a notch 8 and rib 7 of the inflatable shell 16. Also shown in FIG. 5 are chambers 6 on either side of the rib 7. From FIG. 5, it can be seen that the portions of the inner surface 15 immediately adjacent to the notches 8 will not come in contact with one another upon inflation of a gastric band 10 having an inflatable shell 16 so designed. This prevents wear and rubbing of the inner surface 15. Also as a result of the notch 8, a crease will not form in the inner surface 15 of the inflatable shell 16. Further, because of

this, the chamber 6 can be inflated to a much greater volume forming a smaller stoma than similar sized gastric bands known in the prior art.

The effects of the notch 8 can be described as follows: the notch 8 acts as a pre-formed crease in the inflatable shell 16. The notch 8 acts similarly to the crease that may form in gastric bands known in the prior art as it provides a point around which the body portion 11 is allowed to bend the inner surface 15 of the gastric band 10 to form a substantially circular band. One with basic geometry skills will understand 10 that the inner surface 15 and the body portion 11 have substantially similar lengths. As a result of this, if the body portion 11 and the inflatable shell 16 are not pre-formed in a circle, when they are subsequently bent into a circular form, the interior surface 15 must in some fashion eliminate a portion of its overall length to form a circle having a smaller inner circumference than outer circumference. This reduction in circumference has heretofore occurred in prior art gastric bands through the formation of undesirable creases on the inner stomach-facing surface of the gastric band, resulting in 20 a reduced range of inflation for such bands. The formation of these creases alleviates the material stresses in forming the circular shape, but causes point loading at the top and bottom of the creases as well as providing a point of friction between 16 in a circle with pre-formed notches 8, the aforementioned stresses are drastically reduced because the notch 8, alone or in combination with a rib 7, is formed in a fashion that prevents opposing sides of the notch 8 from buckling and reduces stress, while allowing for a great range of inflation 30 versus prior art devices. Additionally, the effects of the point loading associated with the extremities of the crease can be alleviated by the notch $\mathbf{8}$, especially when the notch $\mathbf{8}$ is formed in conjunction with a reinforcing rib 7.

In practice, the gastric band is placed in an encircling 35 position around the stomach using known surgical techniques, including, preferably laparoscopy. Laparoscopic placement is accomplished by introducing the fill tube 14 through a laparoscopic cannula (not shown) into the patient's abdomen. Laparoscopic placement begins with blunt dissec- 40 tion behind the stomach, usually two to three centimeters below the gastro-esophageal junction. Typically, the end of the fill tube 14 and the tail end 13 are passed around the stomach and drawn through the buckle 19, past the exit side 20 so that the belt tab 17 and the buckle 19 are releasably 45 locked together. In this sense, the band is a "one-size-fits-all" device—like that described by Vincent—but because of its notched design, the gastric band is adjustable over a greater range without creasing or folding than Vincent and other known prior art bands.

The stoma—the narrow opening in the stomach created by the band—may be adjusted after the band is secured in this single position. Prior art gastric bands employ an adjustable balloon portion that is used for post-operative adjustment of the stoma as necessary. These adjustable balloons, as dis- 55 cussed above, are prone to creasing. The pre-formed notches 8, chambers 6 and ribs 7 of the inflatable gastric band 10 described herein provide for increased fill volumes, e.g. up to 10 cc, without wrinkles or folds forming in the shell. As in the Vincent band, the inflatable shell 16 is preferably coextensive 60 with the inner stomach-facing surface 15 of the band between the belt tab 17 and the buckle 19. The interior of the inflatable shell 16 is in fluid communication with an injection reservoir, remote pump, pressure reservoir or other adjustment means (not shown) via fill tube 14, as with prior art adjustable gastric 65 bands. The inflatable shell 16 is gradually inflated with saline or other biocompatible fluid via the adjustment means such

6

that the inflatable shell **16**, and in particular the inner surface **15** thereof presses on and constricts the stomach underlying the band. This results in a decrease of the opening (stoma) inside the stomach directly under the encircling gastric band **10**

During inflation of the gastric band 10, the notches 8 and the ribs 7 resist deflection. At the same time, the chambers 6 do not comparatively resist deflection. This results in the areas of the inflatable shell 16 where the ribs 7 are located forming deeper notches 8 upon inflation. Accordingly, these notches 8 reduce the stresses in the inflatable shell 16 and reduce the potential for crease fold failure by eliminating contact between the two sides of the notch 8.

Despite the addition of the notches 8 and ribs 7, the gastric band 10 forms a substantially circular constriction around the stomach upon inflation. The chambers 6 of the inflatable shell 16 direct the locations of inflation. Because of the greater deflections of the inflatable shell 16 in the chambers 6 as compared to the area of the notches 8 and ribs 7, the gastric band 10, and in particularly the inner surface 15 is prevented from pinching the surface of the stomach between two chambers 6 when in its inflated state, thereby reducing the potential for patient discomfort and necrosis.

of the creases as well as providing a point of friction between two facing sides of the crease. By forming the inflatable shell 16 in a circle with pre-formed notches 8, the aforementioned stresses are drastically reduced because the notch 8, alone or in combination with a rib 7, is formed in a fashion that prevents opposing sides of the notch 8 from buckling and reduces stress, while allowing for a great range of inflation versus prior art devices. Additionally, the effects of the point loading associated with the extremities of the crease can be alleviated by the notch 8, especially when the notch 8 is formed in conjunction with a reinforcing rib 7.

In practice, the gastric band is placed in an encircling position around the stomach using known surgical techniques, including, preferably laparoscopy. Laparoscopic placement is accomplished by introducing the fill tube 14

Another embodiment of the present invention is an inflatable gastric band with an inflatable shell that is separated into multiple, isolated inflatable compartments or chambers. The inflation of the isolated chambers may or may not be circular, but will not crease, wrinkle or fold. Each isolated chamber may be inflated separately or simultaneously with other isolated chambers and will expand without creasing, wrinkling or folding. A compartmentalized gastric band allows for even greater adjustability and fill volume ranges than current gastric bands while reducing the potential for fatigue failure or crease fold failure.

For example, it may be desirable to reduce the size of the stoma in a particular direction. In such instances, a chamber on that side of the gastric band could be inflated without changing the size of the remaining chambers. Accordingly, greater flexibility is available in a device having isolated chambers that may be independently filled and adjusted. Such an arrangement requires independent filling pathways for each chamber.

The design of the present invention has been described for use in gastric banding devices, but may also be incorporated into any inflatable or expandable device that uses silicone or other elastomeric or polymeric materials where there may be a concern over crease fold failure.

Although the invention has been particularly shown and described with reference to certain preferred embodiments, it will be readily appreciated by those of ordinary skill in the art that various changes and modifications may be made therein, without departing from the spirit and scope of the invention.

It is intended that the claims be interpreted as including the foregoing as well as various other such changes and modifications

The invention claimed is:

- 1. A gastric band for the treatment of obesity suitable for 5 laparoscopic placement around the stomach of a patient to create a stoma comprising:
 - a body member configured to encircle the stomach; and an encompassing member having an inner wall and an outer wall wherein at least part of the body member is 10 located between the inner wall and the outer wall of the encompassing member;
 - the inner wall being continuous along a length of the body member encircling the stomach and having an inflatable portion, the inflatable portion including at least one 15 notch defining a plurality of chambers, wherein the plurality of chambers have a width that extends beyond the width of the outer wall, and wherein the notch is configured to substantially eliminate at least one of creasing, folding or wrinkling along the inner wall.
- 2. The gastric band of claim 1, wherein the chambers are in fluid communication with one another.
- 3. The gastric band of claim 1, wherein the chambers are further defined by at least one rib adjacent to the at least one notch
- **4**. The gastric band of claim **1**, wherein the chambers are in fluid isolation from one another.
- **5**. The gastric band of claim **1**, wherein the encompassing member is preformed in a curved configuration.
- **6**. The gastric band of claim **1**, wherein the body member is 30 affixed to the outer wall.

R

- 7. A gastric band for the treatment of obesity suitable for laparoscopic placement around the stomach of a patient to create a stoma comprising:
 - an elongated body member having connectible ends configured to encircle the stomach; and
 - an encompassing member having an inner wall and an outer wall wherein at least part of the body member is located between the inner wall and the outer wall of the encompassing member and is affixed to the outer wall;
 - the inner wall being continuous along a length of the body member encircling the stomach and having an inflatable portion, the inflatable portion including a plurality of notches defining a plurality of chambers, wherein the plurality of notches are configured to substantially eliminate at least one of creasing, folding or wrinkling along the inner wall.
- **8**. The gastric band of claim **7**, wherein the chambers extend beyond the width of the body member.
- 9. The gastric band of claim 7, further comprising a fill tube 20 for inflation of the inflatable portion.
 - 10. The gastric band of claim 7, wherein one of the connectible ends of the elongated body member further comprises a clasp for receiving a portion of the elongated body member to secure the gastric band in a curved configuration.
 - 11. The gastric band of claim 10, wherein the connectible ends of the elongated body member are configured to be releasably secured.
 - 12. The gastric band of claim 7, further comprising at least

* * * * *



专利名称(译)	抗疲劳胃束带装置				
公开(公告)号	<u>US8382780</u>	公开(公告)日	2013-02-26		
申请号	US12/851437	申请日	2010-08-05		
[标]申请(专利权)人(译)	BIRK哈内尔				
申请(专利权)人(译)	BIRK哈内尔				
当前申请(专利权)人(译)	ALLERGAN , INC.				
[标]发明人	BIRK JANEL				
发明人	BIRK, JANEL				
IPC分类号	A61B17/08 A61F2/02 A61F2/00 A61F5/00 A61M29/00				
CPC分类号	A61F5/0033 A61F5/005 A61F5/0066				
代理人(译)	多诺万STEPHEN				
优先权	PCT/US2003/026678 2003-08-26 V 60/407219 2002-08-28 US	WO			
其他公开文献	US20100324359A1				
外部链接	Espacenet USPTO				

摘要(译)

公开了一种抗疲劳的可充气胃束带装置,其适于腹腔镜放置在患者的胃周围以治疗肥胖症,并且公开了这种治疗方法。该装置包括具有腔室可膨胀构件的胃束带,该腔室基本上与带的内部胃面对面共同延伸,在调节时不会折皱,起皱或折叠,从而沿着内圆周呈现基本上光滑的轮廓,并且避免会员本身的疲劳或失败。还公开了一种具有多个可充气隔室或腔室的胃带,其可以一起或单独地充气。

